High Potency Active Pharmaceutical Ingredient (HPAPI)


Pune, November 19, 2021 (GLOBE NEWSWIRE) – The Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market is expected to reach around US $ 51.03 billion by 2031 due to the increasing incidence of chronic diseases such as COPD, asthma, cancer and the increasing investments for the development of innovative drugs.

Growth drivers

The increasing focus of pharmaceutical companies on the development of potent compounds has increased the opportunities for manufacturers of HPAPIs. Pharmaceutical companies are increasingly investing in RandD activities to develop potent drugs as well as to expand their HPAPI manufacturing sites. For example, in September 2020, Sequens, a manufacturer of pharmaceutical ingredients, opened a high-potency active pharmaceutical production unit in Villeneuve-La-Garenne, France. An investment of US $ 35 million has been made for this facility. Such initiatives are expected to fuel the growth of the HPAPI market during the projected period.

The global high potency active pharmaceutical ingredients market has been analyzed from five perspectives: product, drug type, manufacturer type, application, and region.

Request a sample report on: https://growthplusreports.com/request-sample-report/?high-potency-active-pharmaceutical-ingredient-hpapi-market

Extracts from “Segmentation by product”

On the basis of product, the market for high potency active pharmaceutical ingredients has been segmented into synthetic HPAPI and biotechnology HPAPI. The Biotech HPAPI segment is expected to be the fastest growing segment in the HPAPI market. Factors such as advancements in HPAPI manufacturing technologies, increasing demand for biologics, and increasing investments for RandD in new drugs are contributing to the growth of this segment.

Extracts from “Segmentation by region”

Regionally, the global high potency active pharmaceutical ingredients market has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). North America dominated the high potency active pharmaceutical ingredients market holding the largest market share in 2020. The increasing prevalence of various diseases such as cancer, the increasing investments of regional pharmaceutical companies for new RandD activities drugs, presence of large number of HPAPI manufacturers and increasing demand for potent drugs are some of the factors driving the growth of HPAPI market in North America.

Extracts from “Competitive Landscape”

Some of the major players operating in the global high potency active pharmaceutical ingredients market include:

  • Pfizer Inc
  • Merck and Co., Inc
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Mylan NV
  • AbbVie Inc
  • Eli Lilly and company
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltée
  • AstraZeneca
Cover of the report Details
Forecast period 2021 to 2031
Forecast period 2021 to 2031 CAGR 7.1%
Market value 2031 $ 51.03 billion
Year of reference 2020
Historical data 2018 and 2019
Number of pages 100 – 120
Covered segment Product, drug type, manufacturer type, application

Get a discount now at https://growthplusreports.com/check-discount/?high-potency-active-pharmaceutical-ingredient-hpapi-market


    1. Market ecosystem
    2. Geographical scope
    3. Calendar under consideration
      1. Historical years – 2018 and 2019
      2. Baseline year – 2020
      3. Planned years – 2021 to 2031
    4. Currency used in the report
    1. Research approach
    2. Data collection methodology
    3. Information source
      1. Secondary sources
      2. Primary sources
    4. Market estimation approach
      1. From bottom to top
      2. From top to bottom
    5. Market forecasting model
    6. Limits and assumptions
    1. Current market trend (COVID-19 perspective)
    2. Pipeline assessment
    3. Key players and their competitive positioning (2020)
    1. Conductors
    2. Constraints / Challenges
    3. Opportunities
    1. Synthetic
    2. biotechnology

COT continues.


  • Powered with free analyst hours and expert interviews with every report
  • Comprehensive quantitative and qualitative information at segment and sub-segment level
  • Trends and outlook for the impact of Covid 19
  • Granular information at global / regional / country level
  • In-depth information on market dynamics (drivers, constraints, opportunities) and the business environment
  • Global coverage of the competitive landscape
  • Winning imperatives
  • Exhaustive coverage of “strategic developments” recorded by the main market players


  • Distributor landscape assessment
  • Price information
  • Customer rating
  • Analysis of investments and initiatives
  • “Company profile” of the main players

Speak to an analyst to find out the impact of Covid-19 on this industry: https://growthplusreports.com/speak-to-analyst/?high-potency-active-pharmaceutical-ingredient-hpapi-market

About Us:

Growth + Reports is part of GRG Health, a global health knowledge services company. We are proud to be members of EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth + service portfolio leverages our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create solutions. scalable and revolutionary that prepare them for future growth and success.

We have been recognized by the prestigious CEO magazine as “Most Innovative Healthcare Market Research Company in 2020.


Comments are closed.